Mark H. O’Hara

Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial

Gregory L. Beatty, Mark H. O’Hara, Simon F. Lacey et al. · Gastroenterology · 2018 · 500 citations · Full text

Medicine, Immunology, Oncology +12

Hepatocytes direct the formation of a pro-metastatic niche in the liver

Jae W. Lee, Meredith L. Stone, Paige M. Porrett et al. · Nature · 2019 · 423 citations · Full text

Medicine, Cell Biology, Oncology +12

An NK-like CAR T cell transition in CAR T cell dysfunction

Charly R. Good, M. Ángela Aznar, Shunichiro Kuramitsu et al. · Cell · 2021 · 401 citations · Full text

Life Sciences, Cell Biology, Immunology +12

Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers

Andrew R. Haas, János L. Tanyi, Mark H. O’Hara et al. · Molecular Therapy · 2019 · 371 citations · Full text

Life Sciences, Immunology, Oncology +17

Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial

Lacey Padrón, Deena M. Maurer, Mark H. O’Hara et al. · Nature Medicine · 2022 · 350 citations · Full text

Medicine, Oncology, Pharmacology +15